2017 American Society of Hematology Annual Meeting

December 9-12, 2017; Atlanta, Georgia
This program provides coverage of the 2017 ASH annual meeting with summary slidesets and expert analyses of key results on hematologic malignancies, including lymphomas/CLL, leukemias, multiple myeloma, and novel targeted therapies, as well as on nonmalignant hematologic disorders.

Share

Program Content

Activities

Key Studies ASH 2017
Preview of ASH 2017: Key Expert-Selected Studies
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2017

Activities

R/R HCL: Vemurafenib + Rituximab
HCL-PG03: Phase II Trial of Vemurafenib + Rituximab in Patients With Relapsed/Refractory Hairy Cell Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2017

Acalabrutinib in R/R MCL
ACE-LY-004: Phase II Trial of BTK Inhibitor Acalabrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2017

CLL: Venetoclax + Ibrutinib
Phase II Trial of Venetoclax + Ibrutinib in Patients With Relapsed/Refractory or Untreated High-Risk CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

Ibrutinib in R/R MCL
Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma: 3.5-Year Follow-up of a Pooled Analysis of 3 Clinical Trials
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2017

First-line Len + Ritux in MCL
Extended Follow-up of Mantle Cell Lymphoma Patients Treated With First-line Lenalidomide + Rituximab
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

Brentuximab Vedotin + AVD in cHL
ECHELON-1: Phase III Trial of First-line Brentuximab Vedotin + AVD Chemotherapy in Advanced Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

Nivolumab After PD in R/R cHL
Analysis of Nivolumab Continued Beyond Progression in Patients With R/R Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

R/R DLBCL: Polatuzumab Vedotin
Randomized Phase II Trial of Polatuzumab Vedotin Addition to Bendamustine + Rituximab in Patients With R/R DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

JULIET: CART in R/R DLBCL
JULIET: Phase II Primary Analysis of CAR T-Cell Therapy Tisagenlecleucel in Adult Patients With Relapsed/Refractory DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

MURANO: VEN + R in R/R CLL
MURANO Interim Analysis: Venetoclax + Rituximab vs Bendamustine + Rituximab in Patients With Relapsed/Refractory CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

R/R cHL: BV + Nivolumab
Phase I/II Study of Brentuximab Vedotin + Nivolumab for Patients With R/R Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2017

R/R CLL: Ibrutinib + Venetoclax
CLARITY: Feasibility Study of Combination Ibrutinib + Venetoclax in R/R CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2017

JCAR017 in R/R NHL
CAR T-Cell Therapy JCAR017 in R/R DLBCL From TRANSCEND NHL 001: Correlation Between Patient Characteristics and Clinical Outcomes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2017

MAINTAIN: BR + Ritux Maint in FL
Phase III MAINTAIN: Extended Rituximab Maintenance in Follicular Lymphoma After First-line Bendamustine + Rituximab
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2017

Activities

Inotuzumab + Bosutinib
Interim Report: Inotuzumab Ozogamicin + Bosutinib in R/R Ph+ ALL or CML in Lymphoid Blast Phase
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

EURO-SKI: TKI Cutoffs in CML
EURO-SKI: Defining Cutoffs for Tyrosine Kinase Inhibitor Cessation in Patients With Chronic Myeloid Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

Midostaurin Maintenance
Midostaurin Maintenance After Midostaurin Plus Chemotherapy in FLT3-Mutated AML: Post Hoc Analysis in RATIFY
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2017

Gilteritinib in ND AML
Gilteritinib With Induction and Consolidation Chemotherapy for Newly Diagnosed AML: Preliminary Phase I Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2017

NGS for MRD in AML
Prospective Molecular MRD Detection in AML by Next-Generation Sequencing
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

RATIFY: <i>NPM1</i> and <i>FLT3</i>
Prognostic Role of NPM1/FLT3-ITD Genotypes in AML: Analysis of the RATIFY Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

mIDH Inhibition in AML
Phase I Study: Ivosidenib or Enasidenib + Standard Induction Chemotherapy in Newly Diagnosed AML With IDH1/IDH2 Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

CPX-351 in High-Risk AML
CPX-351 in Patients With Newly Diagnosed AML at High Risk for Induction Mortality: Initial Phase II Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2017

Venetoclax + LDAC in AML
Phase I/II Study of Venetoclax + Low-Dose Cytarabine in Untreated, Elderly Patients With AML: Outcomes at 1 Year
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2017

HOVON97: Azacitidine Maint
Phase III HOVON97: Azacitidine Maintenance in Older Patients With AML and Refractory Anemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2017

Nivolumab + IA in AML
Phase II Study: Frontline Cytarabine and Idarubicin + Nivolumab in Newly Diagnosed AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2017

Nilotinib + PegIFN in CP CML
Phase III PETALs Interim Analysis: Nilotinib ± PegIFN alfa-2a in Patients With Newly Diagnosed Ph-Positive CP CML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2017

Ivosidenib in AML
Phase I Study: Ivosidenib (AG-120) in Mutant IDH1 Acute Myeloid Leukemia and Other Advanced Hematologic Malignancies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2017

Ponatinib + Steroids in Ph+ ALL
GIMEMA LAL1811: Phase II Study of Frontline Ponatinib + Steroids in Elderly or Unfit Patients With Ph+ ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2017

Activities

GEM-CESAR: KRD + ASCT in SMM
Phase II GEM-CESAR: KRd + ASCT in High-Risk Smoldering Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

BCMA-CART in R/R MM
BCMA-Targeted CAR T-Cells ± Cyclophosphamide in Relapsed/Refractory Multiple Myeloma: Phase I Study
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

IFM 2013-01: PCD in RR MM
Phase II IFM 2013-01: Pomalidomide/Cyclophosphamide/Dexamethasone in Relapsed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

ALCYONE: Dara + VMP
ALCYONE: Daratumumab Plus VMP vs VMP Alone in Newly Diagnosed, Transplantation-Ineligible Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2017

EMN02/HO95: Double vs Single ASCT
Double Vs Single ASCT in Newly Diagnosed Multiple Myeloma: An Analysis of the EMN02/HO95 Phase III Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

Anti-BCMA CART in RRMM
bb2121 Anti-BCMA CAR T-Cell Therapy in Relapsed/Refractory Myeloma: Updated Phase I Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

CD19/BCMA CAR T-cells
Pilot Study: Combined CD19- and BCMA-Targeted CAR T-Cells in Relapsed/Refractory Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

CENTAURUS: Dara in SMM
CENTAURUS: Randomized Study of Daratumumab Dosing in Intermediate- or High-Risk Smoldering Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

MCARH171 CAR T-Cells in MM
Phase I Study: MCARH171 BCMA-Targeted CAR T-Cells in Advanced Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

Phase Ib Pavo: SC Dara in R/R MM
Phase Ib PAVO: Subcutaneous Administration of Coformulated Daratumumab + rHuPH20 in Relapsed/Refractory Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

LEN-ELO Maintenance for MM
Elotuzumab/Lenalidomide/Dexamethasone Maintenance After ASCT in Patients With MM: Preliminary Results From a Phase II Study
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2017

MM: Ixazomib Maintenance
Long-term Ixazomib Maintenance in ASCT-Ineligible Patients With Newly Diagnosed MM: Pooled Analysis of 4 Phase I/II Trials
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2017

POLLUX Follow-up
Daratumumab + Rd vs Rd Alone in Relapsed/Refractory Myeloma: Extended Follow-up From POLLUX
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2017

Activities

HAVEN 4 PK Run-In
HAVEN 4 Preliminary Analysis: Pharmacokinetic Run-in Cohort of Phase III Study of Q4W Emicizumab in Hemophilia A
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2017

Expires: December 10, 2018

HAVEN 2: Emicizumab in Pediatric PwHA
HAVEN 2: Second Interim Analysis of Phase III Single-Arm Study of Emicizumab in Pediatric Patients With Hemophilia A and Factor VIII Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

Expires: December 11, 2018

SUSTAIN: Time to First SCPC
SUSTAIN Subgroup Analysis: Time to First Sickle Cell–Related Pain Crisis in Patients With SCD Receiving Crizanlizumab vs Placebo
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

Expires: December 11, 2018

Cost Impact of Rivaroxaban
EINSTEIN CHOICE: Cost Impact Analysis of Continued Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

Expires: December 11, 2018

SELECT-D: Anticoagulants in VTE
SELECT-D: Dalteparin vs Rivaroxaban Anticoagulation Therapy for Patients With Cancer at Risk of VTE Recurrence
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2017

Expires: December 12, 2018

Eltrombopag for Persistent vs Chronic ITP
Eltrombopag in Adult Patients With Persistent or Chronic ITP: Analysis of a Phase IV Open-Label Study
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2017

Expires: December 12, 2018

Edoxaban vs Dalteparin for VTE
Hokusai VTE-Cancer Study: Edoxaban vs Dalteparin for VTE in Adult Cancer Patients
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

Expires: December 13, 2018

Poor Response to IST in Severe AA
Retrospective Chart Review of Treatment Patterns, Healthcare Resource Utilization in Patients With Severe Aplastic Anemia and Poor Response to Immunosuppression
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2017

Expires: December 13, 2018

Avatrombopag in Chronic ITP
Randomized Phase III Trial of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Previously Treated Chronic ITP
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

Expires: December 14, 2018

Rozanolixizumab in ITP
Phase II Interim Analysis of FcRn Inhibitor Rozanolixizumab in Adult Patients With Primary Immune Thrombocytopenia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2017

Expires: December 19, 2018

Activities

Avadomide (CC-122) + Obinutuzumab in R/R NHL
Phase Ib Study: Avadomide (CC-122) Plus Obinutuzumab in Relapsed/Refractory B-Cell NHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2017

ACE-CL-003: Acalabrutinib + Obinutuzumab in CLL
ACE-CL-003: Phase Ib/II Study of Acalabrutinib + Obinutuzumab in Patients With Untreated or R/R CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2017

HERCULES: Caplacizumab in aTTP
HERCULES: Caplacizumab in Adult Patients With Acquired Thrombotic Thrombocytopenic Purpura
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2017

MAVORIC: Mogamulizumab in CTCL
Phase III MAVORIC: Mogamulizumab vs Vorinostat in Patients With Previously Treated CTCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2017

Brentuximab Vedotin in CTCL
Extended Follow-up From the ALCANZA Phase III Trial of Brentuximab Vedotin vs Methotrexate or Bexarotene for Previously Treated CD30-Positive CTCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2017

Avapritinib in Advanced Systemic Mastocytosis
Phase I Study of KIT D816V Inhibitor Avapritinib (BLU-285) in Advanced Systemic Mastocytosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2017

Faculty

cover img faculity

Christopher W. Ryan, MD

Assistant Professor of Medicine
Division of Hematology & Medical Oncology
Oregon Health and Science University
Portland, Oregon

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology